• Go to navigation
  • Go to content
Welcome to Zomig.info!

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca
  • Zomig
  • Zomig Rapimelt
  • Zomig Nasal Spray

Main navigation

  • Home
  • Is it Migraine?
  • Learn About Migraine
  • Treating Migraine
    • Migraine Screening and Diagnosis
    • Migraine Treatment Guidelines
    • Migraine Treatment Options
    • Migraine Treatment Strategies
      • Step Care Across Attacks
      • Step Care Within Attacks
      • Stratified Care
  • Help For Your Migraine Patients
  • Scientific Opinions
  • Learn about Zomig
  • eDetailing
  • Prescribing Information
  • Migraine Glossary and Useful Links
  • References
  • About AstraZeneca
  • Sitemap

You are here

  • Home
  • Treating Migraine
  • Migraine Treatment Strategies
  • Stratified Care

  • Physicians assess a patient’s migraine, and prescribe initial treatment based on the severity of symptoms and degree of disability and the individual treatment needs of the patient.

    • Stratified Care

    • MIDAS
    • DISC Study

Impact tools such as MIDAS have been proposed as stratification tools for this approach, with the level of the patient’s disability used to determine the appropriate treatment. Allowing for health considerations and patient preferences, those patients with more severe and disabling attacks would generally be prescribed highly effective, migraine-specific medications at the onset of symptoms, while those with less severe attacks may only require simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs).

The large-scale DISC study showed that a stratified-care approach that utilised the MIDAS impact tool was superior to step-care approaches in the treatment of migraine.

Disability assessments and treatment options for migraine sufferers

 

Back to top



Not signed in



  • Register
  • Forgotten password?

Page tools

  • Print
  • Bookmark this page

Clinical Product Summary

  • Zomig Nasal Spray
  • Zomig Rapimelt

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008